Aug 18 (Reuters) - Medicis Pharmaceutical Corp:
* Says settles Solodyn patent issue with Novartis unit Sandoz
* Says it and Sandoz agreed to terminate all legal disputes relating to Solodyn
- SEC filing
* Says Sandoz confirmed the company's patents are valid and enforceable
* Says Sandoz agreed to be permanently enjoined from any further distribution
of generic Solodyn
* Says agreed to release Sandoz from liability arising from any prior sales of
its generic Solodyn
* Says Sandoz has option to market generic version starting November 2011, or
earlier under certain conditions
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says settles Solodyn patent issue with Novartis unit Sandoz
* Says it and Sandoz agreed to terminate all legal disputes relating to Solodyn
- SEC filing
* Says Sandoz confirmed the company's patents are valid and enforceable
* Says Sandoz agreed to be permanently enjoined from any further distribution
of generic Solodyn
* Says agreed to release Sandoz from liability arising from any prior sales of
its generic Solodyn
* Says Sandoz has option to market generic version starting November 2011, or
earlier under certain conditions
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.